248 related articles for article (PubMed ID: 26943580)
1. Altered expression of neuropeptide Y receptors caused by focal cortical dysplasia in human intractable epilepsy.
Li L; Deng J; Liu C; Luo H; Guan Y; Zhou J; Qi X; Li T; Xu ZD; Luan GM
Oncotarget; 2016 Mar; 7(13):15329-38. PubMed ID: 26943580
[TBL] [Abstract][Full Text] [Related]
2. Altered expression of neuropeptide Y, Y1 and Y2 receptors, but not Y5 receptor, within hippocampus and temporal lobe cortex of tremor rats.
Xu X; Guo F; He Q; Cai X; Min D; Wang Q; Wang S; Tian L; Cai J; Zhao Y
Neuropeptides; 2014 Apr; 48(2):97-105. PubMed ID: 24444822
[TBL] [Abstract][Full Text] [Related]
3. Expression of pannexin 1 and 2 in cortical lesions from intractable epilepsy patients with focal cortical dysplasia.
Li S; Zang Z; He J; Chen X; Yu S; Pei Y; Hou Z; An N; Yang H; Zhang C; Liu S
Oncotarget; 2017 Jan; 8(4):6883-6895. PubMed ID: 28036289
[TBL] [Abstract][Full Text] [Related]
4. Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy.
Furtinger S; Pirker S; Czech T; Baumgartner C; Ransmayr G; Sperk G
J Neurosci; 2001 Aug; 21(15):5804-12. PubMed ID: 11466452
[TBL] [Abstract][Full Text] [Related]
5. Temporal lobe epilepsy and focal cortical dysplasia in children: A tip to find the abnormality.
Bartolini L; Whitehead MT; Ho CY; Sepeta LN; Oluigbo CO; Havens K; Freilich ER; Schreiber JM; Gaillard WD
Epilepsia; 2017 Jan; 58(1):113-122. PubMed ID: 27864929
[TBL] [Abstract][Full Text] [Related]
6. FCD Type II and mTOR pathway: Evidence for different mechanisms involved in the pathogenesis of dysmorphic neurons.
Rossini L; Villani F; Granata T; Tassi L; Tringali G; Cardinale F; Aronica E; Spreafico R; Garbelli R
Epilepsy Res; 2017 Jan; 129():146-156. PubMed ID: 28056425
[TBL] [Abstract][Full Text] [Related]
7. Focal Cortical Dysplasia and Refractory Epilepsy: Role of Multimodality Imaging and Outcome of Surgery.
Jayalakshmi S; Nanda SK; Vooturi S; Vadapalli R; Sudhakar P; Madigubba S; Panigrahi M
AJNR Am J Neuroradiol; 2019 May; 40(5):892-898. PubMed ID: 31000525
[TBL] [Abstract][Full Text] [Related]
8. Neuropeptide Y Y5-receptor activation on breast cancer cells acts as a paracrine system that stimulates VEGF expression and secretion to promote angiogenesis.
Medeiros PJ; Jackson DN
Peptides; 2013 Oct; 48():106-13. PubMed ID: 23932937
[TBL] [Abstract][Full Text] [Related]
9. Proton magnetic resonance spectroscopy in focal cortical dysplasia at 3T.
Tschampa HJ; Urbach H; Träber F; Sprinkart AM; Greschus S; Malter MP; Surges R; Gieseke J; Block W
Seizure; 2015 Nov; 32():23-9. PubMed ID: 26552557
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of NPY and Y2 receptors in epileptic brain tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy?
Vezzani A; Sperk G
Neuropeptides; 2004 Aug; 38(4):245-52. PubMed ID: 15337376
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunohistochemical characteristics of type II and type I focal cortical dysplasia.
Yao K; Duan Z; Zhou J; Li L; Zhai F; Dong Y; Wang X; Ma Z; Bian Y; Qi X; Li L
Oncotarget; 2016 Nov; 7(47):76415-76422. PubMed ID: 27811355
[TBL] [Abstract][Full Text] [Related]
12. Expression Patterns of TRPC1 in Cortical Lesions from Patients with Focal Cortical Dysplasia.
Zang Z; Li S; Zhang W; Chen X; Zheng D; Shu H; Guo W; Zhao B; Shen K; Wei Y; Zheng X; Liu S; Yang H
J Mol Neurosci; 2015 Oct; 57(2):265-72. PubMed ID: 26280213
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of HMGB1-TLR4 inflammatory pathway in focal cortical dysplasia type II.
Zhang Z; Liu Q; Liu M; Wang H; Dong Y; Ji T; Liu X; Jiang Y; Cai L; Wu Y
J Neuroinflammation; 2018 Jan; 15(1):27. PubMed ID: 29382328
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of CD47 and CD200 in patients with focal cortical dysplasia type IIb and tuberous sclerosis complex.
Sun FJ; Zhang CQ; Chen X; Wei YJ; Li S; Liu SY; Zang ZL; He JJ; Guo W; Yang H
J Neuroinflammation; 2016 Apr; 13(1):85. PubMed ID: 27095555
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations involving TSC 1 and TSC2 genes in two children with focal cortical dysplasia.
Jha R; Kurup A; Kovilapu UB; Ranjan R; Sondhi V
Brain Dev; 2022 Feb; 44(2):166-172. PubMed ID: 34756499
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo.
Smiałowska M; Domin H; Zieba B; Koźniewska E; Michalik R; Piotrowski P; Kajta M
Neuropeptides; 2009 Jun; 43(3):235-49. PubMed ID: 19318226
[TBL] [Abstract][Full Text] [Related]
17. Neuropeptide Y receptor interactions regulate its mitogenic activity.
Czarnecka M; Lu C; Pons J; Maheswaran I; Ciborowski P; Zhang L; Cheema A; Kitlinska J
Neuropeptides; 2019 Feb; 73():11-24. PubMed ID: 30503694
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Expression of miR-323a-5p in Patients with Refractory Epilepsy Caused by Focal Cortical Dysplasia.
Che N; Zu G; Zhou T; Wang X; Sun Y; Tan Z; Liu Y; Wang D; Luo X; Zhao Z; Zhang Y; Wei M; Yin J
Genet Test Mol Biomarkers; 2017 Jan; 21(1):3-9. PubMed ID: 27824513
[TBL] [Abstract][Full Text] [Related]
19. Complex Patterns of GABAergic Neuronal Deficiency and Type 2 Potassium-Chloride Cotransporter Immaturity in Human Focal Cortical Dysplasia.
Han P; Welsh CT; Smith MT; Schmidt RE; Carroll SL
J Neuropathol Exp Neurol; 2019 Apr; 78(4):365-372. PubMed ID: 30856249
[TBL] [Abstract][Full Text] [Related]
20. Levetiracetam prevents changes in levels of brain-derived neurotrophic factor and neuropeptide Y mRNA and of Y1- and Y5-like receptors in the hippocampus of rats undergoing amygdala kindling: implications for antiepileptogenic and mood-stabilizing properties.
Husum H; Bolwig TG; Sánchez C; Mathé AA; Hansen SL
Epilepsy Behav; 2004 Apr; 5(2):204-15. PubMed ID: 15123022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
